Literature DB >> 23700173

Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome.

Anne-Laure Sellier-Leclerc1, Emre Belli, Valérie Guérin, Peter Dorfmüller, Georges Deschênes.   

Abstract

BACKGROUND: We report a 7-year-old boy with high-degree steroid-dependent idiopathic nephrotic syndrome (SDNS) who went into remission with rituximab (RTX) maintenance therapy. CASE-DIAGNOSIS/TREATMENT: Four months after this patient received his first RTX infusion, there was a progressive and sustained decrease of immunoglobulin (Ig)G and IgM levels. Thirteen months after the initiation of RTX therapy he was in sustained remission without any steroid or oral immunosuppressive therapy; however, B cell depletion was still present. At this time he developed a fulminant myocarditis due to enterovirus. Despite aggressive treatment and the administration of intravenous polyvalent immunoglobulins there was no clinical improvement. He successfully underwent heart transplant surgery.
CONCLUSIONS: We conclude that B cell depletion with RTX is efficacious in the treatment of paediatric SDNS but that it may be associated with severe infectious complications. Therefore, we recommend a close monitoring of Ig levels in children who have received RTX therapy and a supplementation with intravenous Ig as soon as the Ig levels fall below the lower limit of the normal range.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23700173     DOI: 10.1007/s00467-013-2485-9

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  26 in total

1.  Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome.

Authors:  Markus J Kemper; Jutta Gellermann; Sandra Habbig; Rafael T Krmar; Katalin Dittrich; Therese Jungraithmayr; Lars Pape; Ludwig Patzer; Heiko Billing; Lutz Weber; Martin Pohl; Katrin Rosenthal; Anne Rosahl; Dirk E Mueller-Wiefel; Jörg Dötsch
Journal:  Nephrol Dial Transplant       Date:  2011-11-09       Impact factor: 5.992

2.  Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia.

Authors:  Mitsufumi Nishio; Tomoyuki Endo; Katsuya Fujimoto; Katusya Fujimoto; Norihiro Sato; Toshiya Sakai; Masato Obara; Koki Kumano; Koti Kumano; Koichiro Minauchi; Takao Koike
Journal:  Eur J Haematol       Date:  2005-12       Impact factor: 2.997

3.  Severe respiratory adverse events associated with rituximab infusion.

Authors:  Koichi Kamei; Shuichi Ito; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2009-12-19       Impact factor: 3.714

4.  Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.

Authors:  Geraldine Cambridge; William Stohl; Maria J Leandro; Thi-Sau Migone; David M Hilbert; Jonathan C W Edwards
Journal:  Arthritis Rheum       Date:  2006-03

5.  Rituximab efficiency in children with steroid-dependent nephrotic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Marie-Alice Macher; Chantal Loirat; Valérie Guérin; Hervé Watier; Michel Peuchmaur; Véronique Baudouin; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2010-03-18       Impact factor: 3.714

6.  Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children.

Authors:  Koichi Kamei; Shuichi Ito; Kandai Nozu; Shuichiro Fujinaga; Makiko Nakayama; Mayumi Sako; Mari Saito; Maki Yoneko; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2009-05-07       Impact factor: 3.714

7.  Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma.

Authors:  Alison R Walker; Anatole Kleiner; Lynn Rich; Charlene Conners; Richard I Fisher; Jennifer Anolik; Jonathan W Friedberg
Journal:  Cancer Invest       Date:  2008-05       Impact factor: 2.176

8.  Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome.

Authors:  Mai Sato; Shuichi Ito; Masao Ogura; Koichi Kamei; Isao Miyairi; Ippei Miyata; Masataka Higuchi; Kentaro Matsuoka
Journal:  Pediatr Nephrol       Date:  2012-09-05       Impact factor: 3.714

9.  Use of intravenous immunoglobulin compared with standard therapy is associated with improved clinical outcomes in children with acute encephalitis syndrome complicated by myocarditis.

Authors:  Girish Chandra Bhatt; Jhuma Sankar; K P Kushwaha
Journal:  Pediatr Cardiol       Date:  2012-05-16       Impact factor: 1.655

10.  Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.

Authors:  Nils Venhoff; Nora M Effelsberg; Ulrich Salzer; Klaus Warnatz; Hans Hartmut Peter; Dirk Lebrecht; Michael Schlesier; Reinhard E Voll; Jens Thiel
Journal:  PLoS One       Date:  2012-05-21       Impact factor: 3.240

View more
  25 in total

Review 1.  Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.

Authors:  Koichi Kamei; Kenji Ishikura; Mayumi Sako; Shuichi Ito; Kandai Nozu; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2018-12-18       Impact factor: 3.714

2.  Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome.

Authors:  Cyrielle Parmentier; Jean-Daniel Delbet; Stéphane Decramer; Olivia Boyer; Julien Hogan; Tim Ulinski
Journal:  Pediatr Nephrol       Date:  2019-11-08       Impact factor: 3.714

Review 3.  Treatment of membranous nephropathy: time for a paradigm shift.

Authors:  Piero Ruggenenti; Fernando C Fervenza; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

4.  Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.

Authors:  Shuichiro Fujinaga; Daishi Hirano; Akira Mizutani; Koji Sakuraya; Akifumi Yamada; Shunsuke Sakurai; Toshiaki Shimizu
Journal:  Clin Exp Nephrol       Date:  2016-08-24       Impact factor: 2.801

5.  Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries.

Authors:  Georges Deschênes; Marina Vivarelli; Licia Peruzzi
Journal:  Eur J Pediatr       Date:  2017-03-16       Impact factor: 3.183

6.  Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome.

Authors:  Shuichiro Fujinaga; Koji Sakuraya; Akifumi Yamada; Yasuko Urushihara; Yoshiyuki Ohtomo; Toshiaki Shimizu
Journal:  Pediatr Nephrol       Date:  2015-01-10       Impact factor: 3.714

Review 7.  Management of fulminant myocarditis: a diagnosis in search of its etiology but with therapeutic options.

Authors:  Bernhard Maisch; Volker Ruppert; Sabine Pankuweit
Journal:  Curr Heart Fail Rep       Date:  2014-06

8.  Nephrotic syndrome: Rituximab in childhood steroid-dependent nephrotic syndrome.

Authors:  Olivia Boyer; Patrick Niaudet
Journal:  Nat Rev Nephrol       Date:  2013-08-13       Impact factor: 28.314

9.  Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.

Authors:  Koichi Kamei; Masao Ogura; Mai Sato; Mayumi Sako; Kazumoto Iijima; Shuichi Ito
Journal:  Pediatr Nephrol       Date:  2015-09-04       Impact factor: 3.714

10.  Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome.

Authors:  Julien Hogan; Claire Dossier; Thérésa Kwon; Marie-Alice Macher; Anne Maisin; Anne Couderc; Olivier Niel; Véronique Baudouin; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2018-08-14       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.